Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.39 |
| ▸ | SMURF1 | Q9HCE7 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30038081 | 0.84 | HTT (0.65) | HTTNOTUMSMURF1MAPTNPSR1 | |
| SCHEMBL2219241 | 0.84 | HTT (0.65) | HTTNOTUMSMURF1MAPTNPSR1 | |
| SCHEMBL3457023 | 0.82 | SLC5A1 (0.59) | SLC5A1SLC5A2MAPTNPSR1TP53 | |
| SCHEMBL17595761 | 0.81 | HTT (0.64) | HTTSLC5A1SLC5A2TP53ALOX12 | |
| SCHEMBL2217305 | 0.78 | HTT (0.46) | HTTNOTUMMAPK14KCNN4NPSR1 | |
| SCHEMBL17321491 | 0.78 | MAPT (0.47) | HTTNOTUMSMURF1MAPTKCNN4 | |
| SCHEMBL3753122 | 0.77 | ALDH1A1 (0.56) | HTTMAPK14MAPTNPSR1ALDH1A1 | |
| SCHEMBL30388059 | 0.76 | WNT3A (0.63) | SMURF1 | |
| SCHEMBL20604113 | 0.76 | WNT3A (0.63) | SMURF1 | |
| SCHEMBL23130794 | 0.76 | MET (0.47) | HTTNOTUMMAPK14MAPTKCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV OF MARYLAND BALTIMORE (US) | 2026-05-21 | — | — | US | disclosed |
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3423452-B1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV MARYLAND (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200299261-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-24 | — | — | US | disclosed |
| US-10723715-B2 | — | — | 2020-07-28 | — | — | US | disclosed |
| US-20190071424-A1 | WNT Signaling Pathway Inhibitors for Treatments of Disease | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-03-07 | — | — | US | disclosed |
| EP-3423452-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | University of Maryland, Baltimore (US) | 2019-01-09 | — | — | EP | disclosed |
| CN-101918395-A | Triazole oxadiazole derivatives | MERCK SERONO SA | 2010-12-15 | — | — | CN | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| EP-2250165-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | Merck Serono S.A. (CH) | 2010-11-17 | — | — | EP | disclosed |
| US-20100137587-A1 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-06-03 | — | — | US | disclosed |
| US-20100137587-A1 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-06-03 | — | — | US | disclosed |
| US-20100137587-A1 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-06-03 | — | — | US | disclosed |
| WO-2009080663-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080663-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | HTT 1192/4885NOTUM 3050/4885SLC5A1 2771/4885 |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | OXA1L, RO60, PDCD11 | HTT 2520/4885NOTUM 4794/4885SLC5A1 2602/4885 |
| US-20200299261-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | HTT 1192/4885NOTUM 3050/4885SLC5A1 2771/4885 |
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | HTT 1192/4885NOTUM 3050/4885SLC5A1 2771/4885 |
| US-20190071424-A1 | WNT Signaling Pathway Inhibitors for Treatments of Disease | WNT1, CTNNB1, WNT3A | HTT 1192/4885NOTUM 3050/4885SLC5A1 2771/4885 |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | HTT 1192/4885NOTUM 3050/4885SLC5A1 2771/4885 |
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | CTNNB1, WNT1, CTNND1 | HTT 1107/4885NOTUM 456/4885SLC5A1 1270/4885 |
| US-20100137587-A1 | Heterocyclic compound and use thereof | REN, AGT, ACE | HTT 3793/4885NOTUM 645/4885SLC5A1 333/4885 |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | HTT 1192/4885NOTUM 3050/4885SLC5A1 2771/4885 |
| US-10723715-B2 | — | CTNNB1, WNT1, CTNNBL1 | HTT 1668/4885NOTUM 1943/4885SLC5A1 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.